

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Shigetoshi KADOTA et al.**

Art Unit: **1614**

Application Number: **10/570,252**

Examiner: **Brian Yong S Kown**

Filed: **March 2, 2006**

Confirmation Number: **7463**

For: **THERAPEUTIC OR PREVENTIVE DRUG FOR OSTEOPOROSIS
COMPRISING ISOTAXIRESINOL DERIVED FROM TAXUS
YUNNANENSIS**

Attorney Docket Number: **062043**

Customer Number: **38834**

AMENDMENT TRANSMITTAL

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

July 20, 2009

Sir:

Transmitted herewith is an Amendment in the above-identified application. The fee has been calculated as shown below.


	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
					RATE	ADD'L FEE		RATE	ADD'L FEE
Total (37 CFR 1.16(c))	13	Minus	20	= 0	X \$26		OR	X \$52	.00
Independent (37 CFR 1.16(b))	4	Minus	3	= 1	X \$110	110.00	OR	X \$220	.00
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(d))					+ \$195		OR	+ \$390	.00
					TOTAL ADD'L FEE	110.00		TOTAL ADD'L FEE	.00

☒ Enclosed please find our payment in the amount of \$220.00 for the additional claims fee in connection with this Amendment.

☒ The Commissioner is hereby authorized to charge payment for any additional fees associated with this communication or credit any overpayment to Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP


Ryan B. Chirnomas
Attorney for Applicants
Registration No. 56,527
Telephone: (202) 822-1100
Facsimile: (202) 822-1111

RBC/nrp